Archives

  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent siRN...

    2025-12-21

    Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent siRNA & mRNA Delivery

    Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a synthetic ionizable cationic lipid widely used in lipid nanoparticle (LNP) formulations for siRNA and mRNA drug delivery. It exhibits a pH-dependent charge, being neutral at physiological pH and positively charged at acidic pH, which minimizes systemic toxicity and enhances endosomal escape (Wang et al., 2022). In preclinical studies, Dlin-MC3-DMA enabled hepatic gene silencing with ED50 values of 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates. Benchmark data and machine learning models confirm its superior efficacy over precursor lipids. APExBIO supplies Dlin-MC3-DMA (SKU: A8791) for research use, and it is recommended for workflows requiring high-potency gene knockdown and mRNA vaccine formulation.

    Biological Rationale

    Lipid nanoparticles (LNPs) have become the primary vehicle for delivering nucleic acids, such as siRNA and mRNA, into mammalian cells. The key challenge is enabling efficient cytoplasmic delivery while minimizing off-target effects and toxicity (Wang et al., 2022). Dlin-MC3-DMA is an ionizable cationic liposome lipid designed to address these goals. It is incorporated into LNPs alongside helper lipids (DSPC), cholesterol, and PEGylated lipids (PEG-DMG), forming stable, biocompatible nanostructures. Its pH-sensitive headgroup ensures that the lipid remains neutral at physiological pH (7.4), reducing systemic toxicity, but becomes positively charged in acidic endosomal environments (pH ≤ 6), promoting endosomal escape and efficient payload release (see Figure 2). This mechanism underlies Dlin-MC3-DMA's widespread use in both siRNA and mRNA delivery, including vaccine applications.

    Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

    Dlin-MC3-DMA functions as an ionizable lipid within LNPs. At physiological pH, its tertiary amine group is predominantly unprotonated, conferring a neutral charge and low plasma toxicity. Upon cellular uptake, LNPs are trafficked into endosomes, where the local pH drops to ~5.5–6.0. Under these acidic conditions, the tertiary amine of Dlin-MC3-DMA becomes protonated, acquiring a positive charge (Wang et al., 2022). This cationic state facilitates electrostatic interactions with anionic endosomal lipids, destabilizing the endosomal membrane and enabling the encapsulated siRNA or mRNA to escape into the cytoplasm. This endosomal escape is essential for gene silencing (siRNA) or protein expression (mRNA). The design also limits cationic charge exposure in circulation, minimizing adverse reactions.

    Evidence & Benchmarks

    • Dlin-MC3-DMA-based LNPs achieved a 1000-fold increase in hepatic gene silencing potency over DLin-DMA in preclinical models (ED50 of 0.005 mg/kg in mice for Factor VII silencing) (Wang et al., 2022).
    • Machine learning models (LightGBM) trained on 325 LNP-mRNA datasets ranked Dlin-MC3-DMA as superior in predicted and empirical mRNA delivery efficacy (Wang et al., 2022).
    • Dlin-MC3-DMA LNPs with an N/P ratio of 6:1 induced higher mRNA expression in vivo compared to LNPs using SM-102, as demonstrated in mouse models (Wang et al., 2022, Table 2).
    • Formulations containing Dlin-MC3-DMA, DSPC, cholesterol, and PEG-lipid have been validated in both mRNA vaccine and siRNA drug pipelines, including COVID-19 vaccine development (Wang et al., 2022).
    • Dlin-MC3-DMA is insoluble in water and DMSO, but soluble in ethanol at 152.6 mg/mL, requiring careful handling for reproducible LNP assembly (APExBIO product page).

    Applications, Limits & Misconceptions

    Dlin-MC3-DMA is extensively cited in literature for its role in advanced LNP formulations for siRNA and mRNA drug delivery. Key applications include:

    • siRNA delivery vehicle: Highly efficient hepatic gene silencing (e.g., Factor VII, TTR) at low doses.
    • mRNA vaccine formulation: Backbone for COVID-19 and other mRNA vaccines due to high encapsulation efficiency and robust in vivo translation.
    • Cancer immunochemotherapy: Used in LNPs delivering immunomodulatory nucleic acids or tumor antigen mRNA.

    For a deeper mechanistic and computational perspective, see this article, which details formulation prediction strategies and how this review extends them by focusing on atomic, quantitative benchmarks. For advanced design principles and translational potential, this resource covers computational insights, while the present article adds direct evidence on clinical benchmarks and workflow integration. For a concise overview of Dlin-MC3-DMA's role as a gold-standard lipid, see this summary; here, we extend by mapping practical parameters and common pitfalls.

    Common Pitfalls or Misconceptions

    • Misconception: Dlin-MC3-DMA LNPs are universally non-toxic. Correction: While reduced toxicity is observed at physiological pH, overexposure or improper pH control can still yield adverse effects.
    • Pitfall: Assuming water or DMSO solubility for stock solutions. Dlin-MC3-DMA is insoluble in both; only use ethanol at ≥152.6 mg/mL for accurate dosing (APExBIO).
    • Misconception: All ionizable lipids are interchangeable in LNPs. Dlin-MC3-DMA consistently outperforms SM-102 and first-generation analogs in mRNA and siRNA delivery (Wang et al., 2022).
    • Pitfall: Overextending to DNA delivery—Dlin-MC3-DMA is optimized for RNA, not DNA payloads.
    • Overlooked: Storage at >-20°C or prolonged solution storage can cause degradation and loss of activity.

    Workflow Integration & Parameters

    Dlin-MC3-DMA is supplied by APExBIO (SKU: A8791) for research use (Dlin-MC3-DMA product page). Recommended protocols involve:

    • Storage: -20°C or below; aliquot and use solutions promptly.
    • Solubilization: Dissolve only in ethanol at concentrations ≥152.6 mg/mL.
    • Formulation: Combine with DSPC, cholesterol, and PEGylated lipids in appropriate molar ratios (commonly 50:10:38.5:1.5 mol%).
    • N/P ratio: Adjust to 6:1 for optimal mRNA encapsulation and delivery (Wang et al., 2022).
    • Quality control: Use dynamic light scattering (DLS) for nanoparticle size and polydispersity; confirm encapsulation efficiency by RiboGreen or PicoGreen assays.

    For troubleshooting, protocol streamlining, and advanced immunomodulatory applications, see this resource, which this review updates by providing parameter-specific benchmarks and addressing common pitfalls.

    Conclusion & Outlook

    Dlin-MC3-DMA remains the benchmark ionizable cationic liposome for high-potency, low-toxicity lipid nanoparticle-mediated gene silencing and mRNA delivery. Its pH-sensitive charge dynamics, robust in vivo efficacy, and validated role in machine-learning-driven formulation design ensure ongoing relevance in nucleic acid therapeutics. As LNP platforms expand into new areas (e.g., personalized vaccines, non-hepatic targets), Dlin-MC3-DMA provides a reliable foundation. For product details and ordering, visit the official APExBIO Dlin-MC3-DMA product page.